Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts.

Schwantes-An TH, Zhang J, Chen LS, Hartz SM, Culverhouse RC, Chen X, Coon H, Frank J, Kamens HM, Konte B, Kovanen L, Latvala A, Legrand LN, Maher BS, Melroy WE, Nelson EC, Reid MW, Robinson JD, Shen PH, Yang BZ, Andrews JA, Aveyard P, Beltcheva O, Brown SA, Cannon DS, Cichon S, Corley RP, Dahmen N, Degenhardt L, Foroud T, Gaebel W, Giegling I, Glatt SJ, Grucza RA, Hardin J, Hartmann AM, Heath AC, Herms S, Hodgkinson CA, Hoffmann P, Hops H, Huizinga D, Ising M, Johnson EO, Johnstone E, Kaneva RP, Kendler KS, Kiefer F, Kranzler HR, Krauter KS, Levran O, Lucae S, Lynskey MT, Maier W, Mann K, Martin NG, Mattheisen M, Montgomery GW, Müller-Myhsok B, Murphy MF, Neale MC, Nikolov MA, Nishita D, Nöthen MM, Nurnberger J, Partonen T, Pergadia ML, Reynolds M, Ridinger M, Rose RJ, Rouvinen-Lagerström N, Scherbaum N, Schmäl C, Soyka M, Stallings MC, Steffens M, Treutlein J, Tsuang M, Wall TL, Wodarz N, Yuferov V, Zill P, Bergen AW, Chen J, Cinciripini PM, Edenberg HJ, Ehringer MA, Ferrell RE, Gelernter J, Goldman D, Hewitt JK, Hopfer CJ, Iacono WG, Kaprio J, Kreek MJ, Kremensky IM, Madden PA, McGue M, Munafò MR, Philibert RA, Rietschel M, Roy A, Rujescu D, Saarikoski ST, Swan GE, Todorov AA, Vanyukov MM, Weiss RB, Bierut LJ, Saccone NL.

Behav Genet. 2016 Mar;46(2):151-69. doi: 10.1007/s10519-015-9737-3.

PMID:
26392368
2.

A heroin addiction severity-associated intronic single nucleotide polymorphism modulates alternative pre-mRNA splicing of the μ opioid receptor gene OPRM1 via hnRNPH interactions.

Xu J, Lu Z, Xu M, Pan L, Deng Y, Xie X, Liu H, Ding S, Hurd YL, Pasternak GW, Klein RJ, Cartegni L, Zhou W, Pan YX.

J Neurosci. 2014 Aug 13;34(33):11048-66. doi: 10.1523/JNEUROSCI.3986-13.2014.

3.

Pharmacogenetics of OPRM1.

Crist RC, Berrettini WH.

Pharmacol Biochem Behav. 2014 Aug;123:25-33. doi: 10.1016/j.pbb.2013.10.018. Review.

4.

Mu opioids and their receptors: evolution of a concept.

Pasternak GW, Pan YX.

Pharmacol Rev. 2013 Sep 27;65(4):1257-317. doi: 10.1124/pr.112.007138. Review.

5.

RGS17: an emerging therapeutic target for lung and prostate cancers.

Bodle CR, Mackie DI, Roman DL.

Future Med Chem. 2013 Jun;5(9):995-1007. doi: 10.4155/fmc.13.91.

6.

μ-Opioid receptor gene (OPRM1) polymorphism A118G: lack of association in Finnish populations with alcohol dependence or alcohol consumption.

Rouvinen-Lagerström N, Lahti J, Alho H, Kovanen L, Aalto M, Partonen T, Silander K, Sinclair D, Räikkönen K, Eriksson JG, Palotie A, Koskinen S, Saarikoski ST.

Alcohol Alcohol. 2013 Sep-Oct;48(5):519-25. doi: 10.1093/alcalc/agt050.

7.

Mu opioid receptor (OPRM1) as a predictor of treatment outcome in opiate-dependent individuals of Arab descent.

Al-Eitan LN, Jaradat SA, Su SY, Tay GK, Hulse GK.

Pharmgenomics Pers Med. 2012;5:99-111. doi: 10.2147/PGPM.S33351.

8.
9.

Variation in regulator of G-protein signaling 17 gene (RGS17) is associated with multiple substance dependence diagnoses.

Zhang H, Wang F, Kranzler HR, Anton RF, Gelernter J.

Behav Brain Funct. 2012 May 16;8:23. doi: 10.1186/1744-9081-8-23.

10.

The genetics of the opioid system and specific drug addictions.

Levran O, Yuferov V, Kreek MJ.

Hum Genet. 2012 Jun;131(6):823-42. doi: 10.1007/s00439-012-1172-4. Review.

11.

A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys.

Vallender EJ, Rüedi-Bettschen D, Miller GM, Platt DM.

Drug Alcohol Depend. 2010 Jun 1;109(1-3):252-6. doi: 10.1016/j.drugalcdep.2010.01.005.

12.

OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.

Mague SD, Blendy JA.

Drug Alcohol Depend. 2010 May 1;108(3):172-82. doi: 10.1016/j.drugalcdep.2009.12.016. Review.

13.

Initial evidence of an association between OPRM1 and adolescent alcohol misuse.

Miranda R, Ray L, Justus A, Meyerson LA, Knopik VS, McGeary J, Monti PM.

Alcohol Clin Exp Res. 2010 Jan;34(1):112-22. doi: 10.1111/j.1530-0277.2009.01073.x.

14.

The opioid peptides enkephalin and beta-endorphin in alcohol dependence.

Racz I, Schürmann B, Karpushova A, Reuter M, Cichon S, Montag C, Fürst R, Schütz C, Franke PE, Strohmaier J, Wienker TF, Terenius L, Osby U, Gunnar A, Maier W, Bilkei-Gorzó A, Nöthen M, Zimmer A.

Biol Psychiatry. 2008 Dec 1;64(11):989-97. doi: 10.1016/j.biopsych.2008.05.008.

15.
16.
17.

The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk.

Zhang H, Kranzler HR, Yang BZ, Luo X, Gelernter J.

Mol Psychiatry. 2008 May;13(5):531-43.

18.

Pharmacotherapy for alcohol dependence: anticraving medications for relapse prevention.

Jung YC, Namkoong K.

Yonsei Med J. 2006 Apr 30;47(2):167-78. Review.

19.

Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence.

Zhang H, Luo X, Kranzler HR, Lappalainen J, Yang BZ, Krupitsky E, Zvartau E, Gelernter J.

Hum Mol Genet. 2006 Mar 15;15(6):807-19.

Items per page

Supplemental Content

Support Center